#United States #Cancer Treatment #SystImmune #Redmond #Iza-bren

SystImmune, Inc. Announces Presentation of Iza-Bren Data at ASCO 2025

SystImmune, Inc., a biotechnology company focused on advanced cancer therapies, has announced exciting plans for the upcoming American Society of Clinical Oncology (ASCO) 2025 Annual Meeting. The company is set to present two groundbreaking abstracts concerning its investigational drug, izalontamab brengitecan (known as Iza-Bren). This novel treatment shows promise for patients suffering from advanced Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC) with specific driver genomic alterations, particularly those outside of the classic EGFR mutations.

A Closer Look at Iza-Bren

Iza-Bren represents a pioneering approach in the realm of cancer therapeutics. It is a bispecific antibody-drug conjugate (ADC) that targets both EGFR and HER3. By interfering with the growth signals of cancer cells, Iza-Bren aims to reduce tumor proliferation and ultimately induce cancer cell death. This drug is being developed in collaboration between SystImmune and Bristol Myers Squibb, under an exclusive licensing agreement.

In clinical trials, Iza-Bren has exhibited a well-tolerated safety profile alongside promising efficacy across various tumors, some of which have traditionally posed significant treatment challenges.

Clinical Trials and Presentation Details

The data to be presented at ASCO encompass results from multiple clinical studies featuring patients with advanced SCLC and NSCLC who have undergone various prior treatments. Among the key highlights:

• - Presentation of Phase I data from a study evaluating Iza-Bren in NSCLC, focusing on patients with genomic alterations other than classic EGFR mutations.
• - Another presentation will cover similar data for SCLC patients, emphasizing the versatility of Iza-Bren in targeting different cancer types.

These sessions are scheduled for May 30, 2025, between 2:45 PM and 5:45 PM CDT, demonstrating the company's commitment to sharing critical advancements with the medical community.

Future Implications

Jonathan Cheng, M.D., Chief Medical Officer of SystImmune, expressed optimism regarding the results, stating, "Recent data have bolstered our confidence in Iza-Bren's safety profile while highlighting its encouraging efficacy across tumors that have been difficult to treat. It emerges as a promising therapeutic option for patients with limited treatment alternatives."

The ongoing commitment to advancing Iza-Bren through comprehensive clinical trials is a testament to SystImmune's dedication to improving patient outcomes on a global scale. The company continues to explore the potential of Iza-Bren both as a standalone treatment and in combination with existing therapies.

About SystImmune

Located in Redmond, Washington, SystImmune is at the forefront of biopharmaceutical innovation, specializing in bi-specific and multi-specific antibodies, alongside antibody-drug conjugates. The company’s robust pipeline includes several cancer therapeutics currently in various stages of clinical trials, reflecting its mission to combat cancer through cutting-edge drug development.

In conclusion, as new data emerges from ASCO 2025, there is significant hope surrounding Iza-Bren's potential impact on treatment strategies for patients facing advanced lung cancers. The scientific community eagerly anticipates the results, which may pave the way for innovative therapeutic options in oncology.